Breaking News

CCBR-SYNARC, BioClinica To Merge

By Kristin Brooks | January 16, 2014

Jeffrey McMullen appointed chairman

CCBR-SYNARC and BioClinica have signed an agreement to merge, creating a global provider of outsourced clinical services from centers throughout Asia, Europe and The Americas. The combined company will offer a portfolio of services for conducting and managing global clinical trials. The transaction is expected to close in 1Q14. Financial terms were not disclosed.
Jeffrey McMullen, vice chairman of inVentiv Health, Inc., will serve as chairman of the combined company. Mark Weinstein, president and chief executive officer of BioClinica, will serve as chief executive officer.
The combined company will offer medical imaging services across multiple therapeutic areas, a worldwide network of research centers dedicated to recruiting patients for global trials, provide technology and consulting services, monitor cardiac safety of compounds, as well as provide central lab services.
Mr. McMullen said, “This is a ground-breaking merger that will bring together two of the industry’s most experienced providers of specialized clinical trial services. Combining CCBR-SYNARC and BioClinica into a single company will offer customers exceptional scientific expertise and sophisticated technologies to support their drug development processes and accelerate the pace of their innovation.”

Related Contract Manufacturing:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research